Literature DB >> 20356929

Breaking down the barriers: siRNA delivery and endosome escape.

Monika Dominska1, Derek M Dykxhoorn.   

Abstract

RNA interference (RNAi)-based technologies offer an attractive strategy for the sequence-specific silencing of disease-causing genes. The application of small interfering (si)RNAs as potential therapeutic agents requires safe and effective methods for their delivery to the cytoplasm of the target cells and tissues. Recent studies have shown significant progress in the development of targeting reagents that facilitate the recognition of and siRNA delivery to specific cell types. However, most of these delivery approaches are not optimized to enable the intracellular trafficking of the siRNAs into the cytoplasm where they must associate with the RNA-induced silencing complex (RISC) to direct the cleavage of mRNAs bearing complementary binding sites. In particular, the trafficking of siRNAs from endosomes into the cytoplasm represents a major rate-limiting step for many delivery approaches. This Commentary focuses on novel strategies designed to enhance endosomal escape and thereby increase the efficacy of siRNA-mediated gene silencing.

Mesh:

Substances:

Year:  2010        PMID: 20356929     DOI: 10.1242/jcs.066399

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  180 in total

Review 1.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

2.  A cell-penetrating helical polymer for siRNA delivery to mammalian cells.

Authors:  Nathan P Gabrielson; Hua Lu; Lichen Yin; Kyung Hoon Kim; Jianjun Cheng
Journal:  Mol Ther       Date:  2012-05-29       Impact factor: 11.454

Review 3.  RNA interference and cancer therapy.

Authors:  Zhaohui Wang; Donald D Rao; Neil Senzer; John Nemunaitis
Journal:  Pharm Res       Date:  2011-10-19       Impact factor: 4.200

4.  Live cell imaging of duplex siRNA intracellular trafficking.

Authors:  Markus Hirsch; Mark Helm
Journal:  Nucleic Acids Res       Date:  2015-04-13       Impact factor: 16.971

Review 5.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors:  Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal:  Adv Drug Deliv Rev       Date:  2015-12-11       Impact factor: 15.470

Review 6.  Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2011-07

7.  Melittin derived peptides for nanoparticle based siRNA transfection.

Authors:  Kirk K Hou; Hua Pan; Gregory M Lanza; Samuel A Wickline
Journal:  Biomaterials       Date:  2013-02-04       Impact factor: 12.479

8.  Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo.

Authors:  Angela A Alexander-Bryant; Anca Dumitriu; Christopher C Attaway; Hong Yu; Andrew Jakymiw
Journal:  J Control Release       Date:  2015-09-18       Impact factor: 9.776

9.  Attenuation of Maladaptive Responses in Aortic Adventitial Fibroblasts through Stimuli-Triggered siRNA Release from Lipid-Polymer Nanocomplexes.

Authors:  Chad T Greco; Robert E Akins; Thomas H Epps; Millicent O Sullivan
Journal:  Adv Biosyst       Date:  2017-07-20

10.  Imaging mRNA expression levels in living cells with PNA·DNA binary FRET probes delivered by cationic shell-crosslinked nanoparticles.

Authors:  Zhenghui Wang; Ke Zhang; Yuefei Shen; Jillian Smith; Sharon Bloch; Samuel Achilefu; Karen L Wooley; John-Stephen Taylor
Journal:  Org Biomol Chem       Date:  2013-03-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.